This ADC product is comprised of an anti-CD33 monoclonal antibody (cloneh2H12d) conjugated via a linker to SGD-1910. The SGD-1910 is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, calicheamicin binds to DNA, causes DNA damage, and subsequently, induces cell death.
ADC Target
- Alternative Names
- CD33; CD33 molecule; p67; SIGLEC3; SIGLEC-3; myeloid cell surface antigen CD33; gp67; CD33 antigen (gp67); sialic acid binding Ig-like lectin 3; sialic acid-binding Ig-like lectin 3;
- Target Entrez Gene ID
- 945
- Overview
- CD33 or Siglec-3 is a transmembrane receptor expressed on cells of myeloid lineage. It is usually considered myeloid-specific, but it can also be found on some lymphoid cells. It binds sialic acids, therefore is a member of the SIGLEC family of lectins.
ADC Antibody
- Overview
- Anti-CD33 antibody, clone # h2H12d
ADC payload drug
- Description
- Pyrrolobenzodiazepine (PBD) dimmers are highly cytotoxic DNA cross-linking agents. PBDs exert their biological activity through covalent binding via their N10-C11imine/carbinolamine moieties to the C2-amino position of a guanine residue within the minor groove of DNA.
For Research Use Only. NOT FOR CLINICAL USE.
Related Products